Adcetris
brentuximab vedotin · CD30Three xenograft models from human HL and ALCL cell lines
Datroway: animal efficacy model or human cells?
datopotamab deruxtecan · Trop-2
Efficacy evidence
Nude mouse xenografts of human pancreatic cancer, NSCLC and breast cancer
“Four in vivo studies were performed with datopotamab deruxtecan (Dato-DXd) administered intravenously to nude mouse xenograft models of human pancreatic cancer, non-small cell lung cancer (NSCLC) and breast cancer, with the two latter being in line with the sought indications.”
Why that model
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reviewer's view of the efficacy data
EMA: adequate evidence of anti-tumour activity in Trop2-positive models in vitro and in vivo
“Overall, the primary pharmacodynamic studies provided adequate evidence that datopotamab deruxtecan showed anti-tumour activity against TROP2 positive cancer models in vitro and in vivo.”
Same question, other ADCs
Besponsa
inotuzumab ozogamicin · CD22Subcutaneous xenograft and systemically disseminated ALL mouse models
Decnupaz
pivekimab sunirine · CD123Two BPDCN patient-derived xenograft (PDX) models in NSG mice
Elahere
mirvetuximab soravtansine · FRαOvarian cancer xenograft mouse models (single IV dose)
Emrelis
telisotuzumab vedotin · c-Metc-Met-positive NSCLC cell line-derived and patient-derived xenograft mouse models
Enhertu
fam-trastuzumab deruxtecan · HER2HER2-positive breast cancer xenograft mouse models (e.g., KPL-4 in nude mice)
Kadcyla
ado-trastuzumab emtansine · HER2HER2+ xenografts (BT-474 EI, Calu-3) and MMTV-HER2 transgenic tumor model; growth inhibition in all three at 3 to 31 mg/kg
Mylotarg
gemtuzumab ozogamicin · CD33CD33+ HL-60 leukemia xenograft in mice: >80% tumor growth inhibition
Padcev
enfortumab vedotin · Nectin-4Nectin-4-expressing patient-derived bladder cancer xenografts (AG-B1, AG-B8) in mice: >75% tumor growth inhibition
Polivy
polatuzumab vedotin · CD79bHuman DLBCL and B-cell lymphoma xenografts in mice; in vitro Ramos cytotoxicity
Tivdak
tisotumab vedotin · Tissue factorCervical cancer patient-derived xenograft (PDX) models in mice
Trodelvy
sacituzumab govitecan · Trop-2Mouse xenografts bearing human Trop-2-expressing tumours
Zynlonta
loncastuximab tesirine · CD19CD19-positive human Burkitt lymphoma (Ramos, Daudi) and DLBCL (WSU-DLCL2) xenografts in immunodeficient mice